Skip to content
22decisions home

Research brief · HLS-13

Approving AI Tools Faster in Healthcare Without Losing Control

In editorial reviewPlanned publish date: 3 December 2026
Theme
Risk and governance
For
CISO, Chief AI Officer
The decision
How fast can we approve new AI tools?

Summary

How fast can we approve new AI tools? We map how healthcare and life sciences decision units approach this choice: who decides, who can veto, what AI leaders are doing differently, and what it means for the technology partners they buy from.

The short answer

In healthcare and life sciences, the decision to approve new AI tools is led by the CISO, but the chief risk and compliance officer and the legal and privacy team can stop it. In healthcare and life sciences, any tool that may touch patient or research data faces privacy and validation reviews. A typical large healthcare and life sciences organisation involves around 11.1 executives in AI decisions.

Key questions

  • How long does it take healthcare and life sciences organisations to approve a new AI tool?
  • Who approves AI tools, and who can block them?
  • How do leaders approve faster without losing control?
  • What evidence do approvers expect from vendors?

What the full report covers

  • Who is involved in this decision, who decides, and who can say no
  • How AI leaders approach it differently from laggards
  • What technology leaders should do next
  • What it means for the technology and services partners they buy from

Full report: 8 to 10 pages, PDF.

Evidence basis

  • Calibrated model
  • Cited

How we label evidence is explained in our methodology.

Frequently asked questions

Who decides how to approve new AI tools in healthcare and life sciences?
In our decision-rights model, the CISO decides, with input from the wider decision unit (Calibrated model).
Who can veto it?
The chief risk and compliance officer and the legal and privacy team can approve or block the decision (Calibrated model).
How much are healthcare and life sciences companies hiring for AI?
AI roles make up 1.2% of current job postings at large US healthcare and life sciences companies, with 69 senior AI roles and 7 AI-governance roles (Measured, October 2026).

Get it first

This brief is planned for 3 December 2026. Request early access and we'll send it to you as soon as it is ready.

The same decision in other industries

More from Healthcare & Life Sciences

Get our research in your inbox

One considered briefing a month on how organisations decide on, buy and adopt AI. Unsubscribe at any time.